Natco Pharma Ltd.

US Court of Appeals for the Federal Circuit has given a ruling in NATCO Pharma’s favour by allowing it to launch a copycat version of Copaxone through its marketing partner Mylan Inc during May 2014. Copaxone (Glatiramer Acetate) is used in the treatment of relapsing-remitting multiple sclerosis. The product is estimated to have clocked revenues, in USA, of about $ 3.45 billion during 2012.

Earlier this month, the company received marketing approval for its Rizatriptan Benzoate (Maxalt-MLD) orally disintegrating tablets, 5 mg and 10 mg (base) from US Food & Drug Administration (USFDA).

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.